《Cell》:科学家揭示不同肿瘤类型的免疫特征图谱

2022-08-19 科技部 科技部

本研究为探究癌症的免疫治疗靶点提供了前所未有的宝贵资源。

肿瘤由于其组织来源、驱动突变和周围组织特性的不同而表现出显著的异质性。不同的肿瘤之间可能会享有共同的免疫原型,事实上,在特定肿瘤类型中已经鉴定到不同的免疫细胞亚群和免疫治疗响应性之间强大的原型关系。然而,如何从不同的肿瘤中去找到主要的免疫原型仍不清晰。

近日,发表在《Cell》上的一项题为“Discovering dominant tumor immune archetypes in a pan-cancer census”的研究中,加州大学旧金山分校联合多个研究团队鉴定和分类了12种不同肿瘤类型的免疫特征图谱,通过对T细胞和单核吞噬细胞亚群精细的分类和定义,研究人员从3个粗略的细胞特征(T细胞特征、髓样细胞特征和非免疫的基质细胞特征)入手渐进分析,确定了10个主要免疫原型的稳定图谱,为了解肿瘤免疫以及确定广泛且常见的免疫治疗靶点提供了一个重要的研究框架。

本研究为探究癌症的免疫治疗靶点提供了前所未有的宝贵资源。

论文链接:

https://www.sciencedirect.com/science/article/abs/pii/S0092867421014264?via%3Dihub

注:此研究成果摘自《Cell》,文章内容不代表本网站观点和立场,仅供参考。

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1872503, encodeId=1b2e18e2503e7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Apr 24 02:30:03 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962832, encodeId=82ab19628328a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon May 02 06:30:03 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309255, encodeId=5c7613092559b, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Fri Mar 18 03:30:03 CST 2022, time=2022-03-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1872503, encodeId=1b2e18e2503e7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Apr 24 02:30:03 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962832, encodeId=82ab19628328a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon May 02 06:30:03 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309255, encodeId=5c7613092559b, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Fri Mar 18 03:30:03 CST 2022, time=2022-03-18, status=1, ipAttribution=)]
    2022-05-02 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1872503, encodeId=1b2e18e2503e7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Apr 24 02:30:03 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962832, encodeId=82ab19628328a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon May 02 06:30:03 CST 2022, time=2022-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309255, encodeId=5c7613092559b, content=<a href='/topic/show?id=8dbb29086c6' target=_blank style='color:#2F92EE;'>#免疫特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29086, encryptionId=8dbb29086c6, topicName=免疫特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Fri Mar 18 03:30:03 CST 2022, time=2022-03-18, status=1, ipAttribution=)]

相关资讯

Cancer Discovery:大规模临床试验证实:短期禁食是安全的,能增强抗肿瘤免疫力

越来越多的科学研究表明,除了能减肥,禁食对健康的益处甚至更多,它可以改善代谢健康,促进糖尿病、癌症等疾病的治疗。

Cancer Discovery:这种可以增强肿瘤免疫反应的“神奇”水果,你知道吗?

免疫检查点抑制剂(Immune Checkpoint Inhabitor, ICI)的出现提高了多种恶性肿瘤患者的总体生存率。然而,ICI治疗的耐药问题仍然是限制其临床应用的主要障碍。

FDA癌症临床试验资格标准:非治疗性环境中的可用疗法(草案)

本指南向临床研究人员和申办者提供了关于将尚未接受其癌症可用治疗(通常称为现有治疗选择)的患者纳入非治愈性癌症治疗药物和生物制品的临床试验的建议。

罗伯特·兰格创立非编码RNA疗法公司,引领RNA导向治疗新革命

罗伯特·兰格(Robert Langer)是麻省理工学院(MIT)享有最高荣誉的教授之一,并参与创建了40多家成功的生物技术公司,其中就包括成功研发出首个mRNA疫苗的Moderna公司

JAMA Oncology:“烧死”肿瘤!科学家开发远程加热、磁性引导热种子的癌症新疗法

从长远来看,我们将改变热种子的形状,使其充当可以引导穿过组织的微型切割手术刀,这将使外科医生能够执行远程操作,从而彻底改变非侵入性手术。

J Clin Oncol:PIK3CA激活突变肿瘤的新药物——Copanlisib!

Copanlisib在携带PIK3CA突变的难治性肿瘤中的抗肿瘤活性未来可期!